Boca Raton, Florida, July 15, 2025 / Ortospinenews / -Surgentec®, an innovative leader in orthopedic surgery solutions and minimal column column, is proud to announce the launch of its new Sacroiliac articular fusion system Tilink®-Insite ™. The system, now available in a sterile kit ready for surgery, has already been used successfully in the initial procedures carried out in multiple US sites, receiving strong endorsements of doctors.
The Insite ™ kit presents a complete set of sterile instruments of unique use combined with an advanced 3D titanium implant. By eliminating the need for traditional sterilization, which can be expensive, consume a lot of time and take inherent risks, this sterile solution in one streams surgical preparation and improves the efficiency of the procedure. Designed to reduce the risk of infection and support a minimally invasive approach, the Insite ™ system offers a profitable and prepared option for surgery for doctors seeking to deliver a long -term relief to patients suffering from joint dysfunction if.
The Insite ™ implant incorporates Nano-Superficie patented technology to encourage bone growth in implant and promote a lasting biological fixation. A large central graft window allows a significant graft volume for robust osteointelling through the ilium and the sacrum. The integrated Trellis architecture of the implant offers structural resistance and open porosity to support bone growth throughout the device. The threaded insert eliminates the need for briefcase, minimizing surgical trauma and allowing a gentle and controlled placement through a small small incision, approximately the size of a room.
“Insite ™ has been designed with patients and doctors in mind,” said Travis Greenhalgh, CEO of SurgentC®. “We are offering a system that not only simplifies the procedure with a complete, sterile and only one -use kit, but also provides the greatest opportunity for long -term merger. The strong comments we have received from the first users validate our approach and promotes our mission of transforming attention into the articular fusion of Si.”
Insite ™ expands the growing fusion portfolio of the Sacroiliac articulation of SurgentC®, which includes:
Tilink®-P ™: Fusion device if later known for its compression and controlled transfixation Tilink®-L ™: Implant designed for immediate fixation through an oblique or lateral approach.
“With the incorporation of Insite ™, we now offer surgeons a complete spectrum of options for articulating si,” Greenhalgh added.
SurgentC® plans to make all its joint fusion portfolio of whether available in sterile kit formats for the end of 2025. The company will exhibit Insite ™ along with other flagship technologies this week at the ASPN Pain and Neuroscience in Miami, Florida conference.
Boca mouth -headed, Florida, SurgenteC® is dedicated to developing and manufacturing avant -garde technologies for orthopedic and neurosurgical applications. With a solid innovation pipe, the company will launch several new products in the rest of 2025.
Contacts
Customer service
(561) 990 7882
clientervice@surgentec.com
